Wall Street analysts expect Celgene Co. (NASDAQ:CELG) to report $3.50 billion in sales for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Celgene’s earnings, with the highest sales estimate coming in at $3.62 billion and the lowest estimate coming in at $3.46 billion. Celgene reported sales of $2.98 billion in the same quarter last year, which indicates a positive year over year growth rate of 17.4%. The business is scheduled to report its next quarterly earnings results before the market opens on Thursday, January 25th.

On average, analysts expect that Celgene will report full-year sales of $3.50 billion for the current fiscal year, with estimates ranging from $12.97 billion to $13.14 billion. For the next fiscal year, analysts forecast that the business will post sales of $14.93 billion per share, with estimates ranging from $14.52 billion to $15.83 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Celgene.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. Celgene’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.58 EPS.

CELG has been the subject of several research analyst reports. Robert W. Baird reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene in a report on Thursday, September 21st. Cantor Fitzgerald reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene in a report on Tuesday, September 26th. Morgan Stanley downgraded Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a report on Thursday, October 5th. Royal Bank of Canada reiterated a “buy” rating and issued a $173.00 price objective on shares of Celgene in a report on Thursday, October 5th. Finally, Vetr upgraded Celgene from a “hold” rating to a “buy” rating and set a $146.58 price objective for the company in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Celgene has an average rating of “Buy” and an average price target of $130.95.

Large investors have recently made changes to their positions in the stock. Thompson Davis & CO. Inc. lifted its holdings in Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI lifted its holdings in Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares in the last quarter. Robecosam AG purchased a new position in Celgene in the 3rd quarter worth approximately $114,000. Guidant Wealth Advisors purchased a new position in Celgene in the 3rd quarter worth approximately $119,000. Finally, Capital Bank & Trust Co lifted its holdings in Celgene by 166.8% in the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 517 shares in the last quarter. Institutional investors own 79.85% of the company’s stock.

Shares of Celgene (NASDAQ:CELG) opened at $102.02 on Thursday. Celgene has a twelve month low of $94.55 and a twelve month high of $147.17. The company has a market capitalization of $80,320.00, a PE ratio of 24.06, a P/E/G ratio of 0.67 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

TRADEMARK VIOLATION NOTICE: “$3.50 Billion in Sales Expected for Celgene Co. (CELG) This Quarter” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/18/3-50-billion-in-sales-expected-for-celgene-co-celg-this-quarter.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get a free copy of the Zacks research report on Celgene (CELG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.